<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657926</url>
  </required_header>
  <id_info>
    <org_study_id>APPA-P2-1</org_study_id>
    <nct_id>NCT04657926</nct_id>
  </id_info>
  <brief_title>A Trial of APPA in the Treatment of Knee Osteoarthritis</brief_title>
  <official_title>A Placebo-controlled, Double-blinded, Randomized, Trial Using a Combination of Apocynin and Paeonol (APPA) for the Treatment of Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AKL Research and Development</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NBCD A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AKL Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A placebo controlled study of APPA in 150 participants with Osteoarthritis of the knee&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week&#xD;
      trial of a fixed-dose combination of apocynin and paeonol (APPA) administered orally twice&#xD;
      daily versus placebo twice daily. Approximately 150 subjects will be randomized to one of the&#xD;
      two treatment groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Actual">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC pain score</measure>
    <time_frame>28 days</time_frame>
    <description>change from baseline in WOMAC pain sub-score of the target knee as evaluated at week 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in WOMAC total score and the WOMAC function and stiffness scores at week 4</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in constant, intermittent and total OA pain assessed by ICOAP scores at week 4 Changes from baseline in constant, intermittent and total OA pain assessed by ICOAP scores at week 4</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in WOMAC pain weight-bearing score (questions 1, 2, and 5) and non-weight bearing score (questions 3 and 4) at week 4</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in physical function assessed by the 20 Meter Walk Test gait speed at week 4</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the weekly mean of the average daily pain intensity at Week 4</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area-under-effect curves of the weekly mean of the average daily pain intensity at Week 4</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMERACT-OARSI responder rate at week 4</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of rescue medication calculated as the sum of tablets used, based on pill counts</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time between baseline and first use of rescue medication</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the Patient Global Assessment (PGA) score at week 4</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in quality of life assessed by the EQ5D at week 4</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>28 days</time_frame>
    <description>Nature, incidence and severity of AEs. Changes in laboratory safety parameters, vital signs, 12-lead ECG parameters, and weight</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in serum and urine biomarkers of joint tissue turnover</measure>
    <time_frame>28 days</time_frame>
    <description>At baseline, and during the trial, serum and urine will be collected, for measurement of biomarkers reflecting collagen- and proteoglycan turnover</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to achieve a clinically relevant pain reduction defined as a decrease from baseline of at least 1 points out of 10 in the 11-point average of daily pain score</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to achieve &quot;moderate improvement&quot; and time to achieve &quot;high improvement&quot; in OMERACT-OARSI response</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>APPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) &amp; 2-hydroxy-4-methoxyacetophenone (2H4MA) administered to 75 participants as 2 x 400mg capsules b.d. for 28 days&#xD;
.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules b.d. for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APPA</intervention_name>
    <description>APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) &amp; 2-hydroxy-4-methoxyacetophenone (2H4MA).</description>
    <arm_group_label>APPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is able to read and understand the language and content of the study material,&#xD;
             understand the requirements for study visits, and is willing to provide information at&#xD;
             the scheduled evaluations and appropriate written informed consent has been obtained.&#xD;
&#xD;
          2. Femorotibial osteoarthritis of the knee, according the American College of&#xD;
             Rheumatology (ACR) clinical and radiographic criteria (Altman et al., 1986) (Appendix&#xD;
             A).&#xD;
&#xD;
          3. Radiological OA grade 2 or 3 of the target knee, using the Kellgren-Lawrence method&#xD;
             (Kellgren and Lawrence, 1957) as graded by central, independent reading of X-ray&#xD;
             obtained during screening, or on a recent (within 6 months) X-ray image which fulfills&#xD;
             the protocol specifications for reading.&#xD;
&#xD;
          4. Age between 40 years and 85 years at the time of screening, both included; of either&#xD;
             sex.&#xD;
&#xD;
          5. Pain score rated on an 11-point numerical rating scale of the target knee of ≥ 20 and&#xD;
             ≤ 45 out of 50 in response to the WOMAC pain sub-score (5 questions), at the time of&#xD;
             screening and baseline. The subject should have undergone a washout-period of at least&#xD;
             5 half-lives of any analgesic medication before completing the screening and baseline&#xD;
             questionnaires.&#xD;
&#xD;
          6. Women of child-bearing potential must use a highly effective method of&#xD;
             contraception(please see Appendix B). Postmenopausal status is defined as being&#xD;
             amenorrheic for at least 1 year prior to screening. Sexually active men with a female&#xD;
             partner of childbearing potential must ensure that their female partner uses a highly&#xD;
             effective method of contraception and agree to use condom from enrolment up to at&#xD;
             least 3 months after the study end. Furthermore, male participants must agree not to&#xD;
             donate sperm throughout the study and at least 3 months after he study end.&#xD;
&#xD;
          7. Knee pain in the target knee for 14 days of the preceding month (periarticular knee&#xD;
             pain due to OA and not due to non-OA conditions such as bursitis, tendonitis, etc.)&#xD;
             based on subject report.&#xD;
&#xD;
          8. Inadequate response to or intolerance to analgesics and/or non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) as reported by the subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected hypersensitivity to or previous hypersensitivity reactions to APPA,&#xD;
             or any of the excipients in the investigational product.&#xD;
&#xD;
          2. For women of childbearing potential:&#xD;
&#xD;
               1. Pregnancy (i.e. positive pregnancy test at Screening) or breastfeeding&#xD;
&#xD;
               2. Failure to agree to practice a highly effective method of contraception (see&#xD;
                  Appendix B), from enrolment up to at least 3 months after the study end.&#xD;
&#xD;
          3. For sexually active men with a female partner of childbearing potential: Failure to&#xD;
             agree to ensure that their female partner uses a highly effective method of&#xD;
             contraception, to agree to use condom (see Appendix B) from enrolment up to at least 3&#xD;
             months after the study end, and to agree not to donate sperm throughout the study and&#xD;
             at least 3 months after the study end.&#xD;
&#xD;
          4. Intra-articular delivery of corticosteroids within 3 months or hyaluronic acid within&#xD;
             6 months of screening in the target knee or into any other joint within 30 days of&#xD;
             screening.&#xD;
&#xD;
          5. Systemic corticosteroid treatment of more than 14 days during the past 6 months prior&#xD;
             to screening.&#xD;
&#xD;
          6. Major surgery or arthroscopy of the target knee within the previous year prior to&#xD;
             screening.&#xD;
&#xD;
          7. Planned surgery on either knee within the next 3 months.&#xD;
&#xD;
          8. Use of a currently unapproved investigational drug, device or biologic within 3 months&#xD;
             prior to screening.&#xD;
&#xD;
          9. Presence of inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis,&#xD;
             polymyalgia rheumatica, gout or pseudogout with history of clinical attacks.&#xD;
&#xD;
         10. Current malignancy or treatment for malignancy within the past five years, with the&#xD;
             exception of treated non-melanoma skin cancer, unless affecting the target knee area,&#xD;
             or carcinoma in situ events.&#xD;
&#xD;
         11. Any other abnormal laboratory results or significant medical conditions that the&#xD;
             Investigator believes should preclude the subject's participation in the trial.&#xD;
&#xD;
         12. Prior septic arthritis of the target knee.&#xD;
&#xD;
         13. Known osteoarthritis of the hip(s) if pain in either or both hip(s) exceeds that of&#xD;
             the target knee using the WOMAC Hip Pain sub-score for that hip at the time of&#xD;
             screening&#xD;
&#xD;
         14. Presence of significant radicular back pain, as reported by the subject.&#xD;
&#xD;
         15. Presence of severe pain in either knee, defined as &gt; 45 out of 50 in response to the&#xD;
             WOMAC pain sub-score (5 questions), at the time of screening or baseline, regardless&#xD;
             of the eligibility of the contralateral knee.&#xD;
&#xD;
         16. Body Mass Index &gt; 40.0 kg/m2.&#xD;
&#xD;
         17. Estimated glomerular filtration rate &lt; 30 mL/min using the Modification of Diet in&#xD;
             Renal Disease (MDRD) method.&#xD;
&#xD;
         18. Substantial use of moderate or higher strength opioid medication for the treatment of&#xD;
             pain within 6 weeks before the screening visit, as evaluated by the investigator.&#xD;
&#xD;
         19. Use of duloxetine, pregabalin, or gabapentin within 4 weeks before the baseline visit.&#xD;
&#xD;
         20. History of alcohol or drug abuse within the past 5 years prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asger Bihlet</last_name>
    <role>Study Director</role>
    <affiliation>Nordic Bioscience Clinical Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanos Clinic</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

